Changes in Beneficial Ownership · 4
Revolution Medicines, Inc.
RVMDNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-09-16
- Issuer
- Revolution Medicines, Inc.
- Issuer CIK
- 0001628171
- Trading symbol
- RVMD
- Rule 10b5-1 indication
- Checked
Reporting owner 1
- Name
- Horn Margaret A
- Reporting owner CIK
- 0001294192
- Relationship
- Officer
- Officer title
- Chief Operating Officer
- Address
- REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY, CA, 94063
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-09-16 | S · Form 4[F1] | 76 | D | 195.0083[F2] | 154,571 | D |
| Common Stock | 2026-09-16 | S · Form 4[F1] | 4,891 | D | 199.3032 | 149,680[F3] | D |
Table key
- S · Form 4
- Sale on the market or privately
- D
- Direct
Footnotes
- F1
- Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units.↩ 1↩ 2
- F2
- The transaction was executed in multiple trades at prices ranging from $195.00 to $195.03, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.↩ 1
- F3
- Includes 56,713 restricted stock units.↩ 1
Signature 1
- Signed
- /s/ Jack Anders, as Attorney-in-fact for Margaret A. Horn
- Date
- 2026-09-18
Company context
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. These product candidates are investigational and have not been approved for commercial use in any indication. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit www.revmed.com and follow us on LinkedIn.